Title | Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. | ||
Author | Groarke, J M; Pevear, D C | ||
Journal | J Infect Dis | Publication Year/Month | 1999-Jun |
PMID | 10228078 | PMCID | -N/A- |
Affiliation | 1.ViroPharma Incorporated, Exton, PA 19341, USA. jgroarke@viropharma.com. |
Pleconaril (VP 63843) is a novel orally bioavailable small molecule with broad antipicornavirus (enterovirus and rhinovirus) activity. Ten independently derived pleconaril-resistant variants of coxsackievirus B3 were isolated from cell culture. The molecular basis of drug resistance and the biologic properties of the drug-resistant viruses were investigated. RNA sequence analysis revealed amino acid changes in the drug-binding pocket of the resistant variants. Thermal stability studies showed the drug-resistant viruses to be significantly less stable than wild type virus. When evaluated in a murine model in which wild type virus infection is 100% lethal, the drug-resistant viruses showed attenuated virulence with both reduced mortality and delayed time to death. Virus titers in heart and spleen were dramatically lower in drug-resistant virus-infected mice than in wild type virus-infected animals. The study results indicate that pleconaril-resistant virus variants are attenuated and significantly less virulent than drug-sensitive wild type virus.